AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02178176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education, encouragement
Description: Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
Study NCT03922035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard peri-/post-transplant supportive care
Study NCT03922035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard peri-/post-transplant supportive care
Study NCT03922035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum CBM 588 Probiotic Strain
Description: Given PO
Study NCT00854178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of two anesthetic drugs
Description: Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in glass vials as a lyophilized powder.
Study NCT03644329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The volunteers will not performed the interventions.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg capsule orally once daily for 16 weeks.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5 mg capsule orally once daily for 16 weeks.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.
Study NCT03644329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-load resistance training (LL)
Description: The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
Study NCT03644329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher-load resistance training (HL)
Description: The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
Study NCT03644329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher-volume resistance training (HV)
Description: The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 100-300 mg orally once daily for 24 weeks.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.
Study NCT00441636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
Study NCT00566124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: 0.4 U/kg bw insulin detemir injected s.c. in the thigh.
Study NCT00566124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: 0.4 U/kg bw insulin glargine injected s.c. in the thigh
Study NCT00566124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulatard
Description: 0.4 U/kg bw NPH insulin injected s.c. in the thigh
Study NCT03238391 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic preconditioning
Description: It is mentioned before in arm/group descriptions
Study NCT03238391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: It is mentioned before in arm/group descriptions
Study NCT01759771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4,000 IU of VD3 for at least one year
Study NCT01759771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for at least one year
Study NCT04329364 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Laser Haemorrhoidoplasty (LAH)
Description: Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
Study NCT04329364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open milligan-morgan conventional haemorrhoidectomy
Description: conventional excisional haemorrhoidectomy
Study NCT04346732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Description: Vapocoolant spray
Study NCT00206375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Growth hormone + Synthroid + Lupron
Study NCT00206375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment and puberty
Description: Lupron once a month and growth hormone daily
Study NCT04200365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib will be administered orally once daily for up to 24 months.
Study NCT03947684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Device
Description: The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matching Canakinumab
Description: Subcutaneous injection.
Study NCT00819585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching Colchicine
Description: Capsule orally once daily for 16 weeks.
Study NCT04621669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: 240 mg
Study NCT04621669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: 0.25 mg
Study NCT04621669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium
Description: 10 mg
Study NCT04621669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: 500 mg
Study NCT01632735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Continuing Care
Description: Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
Study NCT01824173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase in the levels of plasma amino acids
Description: Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
Study NCT01824173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate intensity for 45 minutes
Study NCT00970528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay, BAYG5421)
Description: uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
Study NCT00970528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose (Basen)
Description: uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
Study NCT01361945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
Study NCT04995471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In presence RRT - prototype software
Description: Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
Study NCT02840006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia only
Description: Induction drugs: Citrate of fentanyl, atracurium, etomidate
Study NCT04995471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In presence RRT - online platform
Description: RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available.
Study NCT04995471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-RRT - prototype software
Description: Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
Study NCT04995471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-RRT - online platform
Description: RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available.
Study NCT00907582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic cell transplantation
Description: Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3.
Study NCT01899859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR-MD-02; galactoarabino-rhamnogalaturonate
Study NCT01899859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: GR-MD-02 Placebo
Study NCT03811717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST+EX
Description: Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
Study NCT03811717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST
Description: Participants will complete an 8-hour fast.
Study NCT02840006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia and Spinal anesthesia
Description: Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
Study NCT04426500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Direct injection of 0.25% bupivacaine into surgical wounds
Study NCT04426500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: Direct injection of 0.25% bupivacaine into surgical wounds
Study NCT04426500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Direct injection of 0.25% bupivacaine into surgical wounds
Study NCT04426500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided transversus abdominus plane block
Description: bilateral TAP using ultrasound guidance in prostatectomies
Study NCT04174196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Participants will be treated with CC-486 and lenalidomide for 6 cycles
Study NCT04174196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Participants will be treated with CC-486 and lenalidomide for 6 cycles
Study NCT01906866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin 2/5/10 mg
Description: Circadin 2/5/10 mg. Active arm
Study NCT04174196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be initiated to the plasmacytoma after cycle 2
Study NCT00840333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: DOSE BASED ON PATIENTS WEIGHT
Study NCT01906866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study NCT00692510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsule, oral, dose once daily, 7 days
Study NCT00692510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral, dose once daily, 7 days
Study NCT03465436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 100 mg administered orally (PO)
Study NCT03465436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 400 mg administered PO
Study NCT03465436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for lasmiditan or moxifloxacin
Study NCT03465436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg moxifloxacin administered PO
Study NCT04038086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test
Description: Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
Study NCT04038086 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: circadian rhythm
Description: Blood and CSF will be collected five times throughout the day.
Study NCT04038086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: effect of insulin on peptide transport
Description: Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
Study NCT00692510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Description: Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix
Study NCT00692510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Description: Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix
Study NCT02182141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 ES
Study NCT03730194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
Study NCT03730194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime Bank
Description: The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
Study NCT03982576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Description: 4 weeks of Transdermal nicotine patches or nicotine gum
Study NCT03982576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy (NRT)
Description: 4 weeks of Transdermal nicotine patches or nicotine gum
Study NCT03982576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CS-CBT intervention
Description: 4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
Study NCT03982576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Path2Quit
Description: Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
Study NCT03982576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse prevention program
Description: 4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
Study NCT03982576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SmokefreeTXT
Description: NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
Study NCT04314479 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Symptom Assessment and Health Coaching
Description: The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
Study NCT04314479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Assessment and Health Coaching
Description: The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
Study NCT00255086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10mg Memantine
Study NCT00255086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: 10mg placebo pill
Study NCT02530957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation + High flow nasal cannula oxygen
Description: In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
Study NCT02530957 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non invasive ventilation
Description: In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
Study NCT00937794 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurobehavioral testing
Description: If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
Study NCT00937794 — intervention group
Intervention type: OTHER
Intervention: Visual and auditory assessments
Description: If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
Study NCT04119427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic therapeutic apparatus 1
Description: After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
Study NCT04119427 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasonic therapeutic apparatus 2
Description: The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
Study NCT02208024 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy